3649 results for «684»
3649 results
Assessing coronaries in ACS with intracoronary imaging
21 May 2026 – From EuroPCR 2026
This session highlights the critical role of intracoronary imaging in evaluating acute coronary syndromes (ACS). It discusses the management of complex lesion morphologies involving calcium and thrombus, the diagnostic power of OCT in decision-making, challenges beyond angiography in right coronary artery pathology, and the identification of...
TAVI sub-studies - Beyond the primary endpoint
21 May 2026 – From EuroPCR 2026
This session reviews key sub-studies from major TAVI trials that extend beyond primary endpoints to provide a deeper understanding of valve performance and patient outcomes. It covers comparisons between balloon-expandable and self-expanding valves, long-term real-world data on the Myval valve, echocardiographic outcomes, composite endpoint analyses, and...
Diagnosis and management of INOCA and ANOCA
21 May 2026 – From EuroPCR 2026
This session focuses on the diagnosis and management of ischemia and angina with non-obstructive coronary arteries (INOCA and ANOCA). It presents safety data from coronary function testing, patient outcomes after comprehensive ischemia assessment, and endotype-specific treatment effects. Further topics include coronary sinus reducer therapy, the impact...
New evidence in coronary physiology for microvascular assessment
21 May 2026 – From EuroPCR 2026
This session highlights new evidence in coronary physiology related to microvascular assessment. Topics include endothelial dysfunction in angina with non-obstructive arteries, the prognostic value of microvascular resistance metrics, natural history studies, and trials aimed at standardizing management of microvascular dysfunction.
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

Author
30 years of primary PCI – a tale of perseverance
16 May 2023
Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.

Author